IL229316B - Genetically engineered growth factor variants - Google Patents

Genetically engineered growth factor variants

Info

Publication number
IL229316B
IL229316B IL229316A IL22931613A IL229316B IL 229316 B IL229316 B IL 229316B IL 229316 A IL229316 A IL 229316A IL 22931613 A IL22931613 A IL 22931613A IL 229316 B IL229316 B IL 229316B
Authority
IL
Israel
Prior art keywords
growth factor
genetically engineered
factor variants
engineered growth
variants
Prior art date
Application number
IL229316A
Other languages
English (en)
Hebrew (he)
Other versions
IL229316A0 (en
Original Assignee
Minerva Biotechnologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minerva Biotechnologies Corp filed Critical Minerva Biotechnologies Corp
Publication of IL229316A0 publication Critical patent/IL229316A0/en
Publication of IL229316B publication Critical patent/IL229316B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
IL229316A 2011-05-09 2013-11-07 Genetically engineered growth factor variants IL229316B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161484052P 2011-05-09 2011-05-09
PCT/US2012/036975 WO2012154759A2 (fr) 2011-05-09 2012-05-08 Variants de facteur de croissance génétiquement modifiés

Publications (2)

Publication Number Publication Date
IL229316A0 IL229316A0 (en) 2014-01-30
IL229316B true IL229316B (en) 2020-02-27

Family

ID=47139949

Family Applications (1)

Application Number Title Priority Date Filing Date
IL229316A IL229316B (en) 2011-05-09 2013-11-07 Genetically engineered growth factor variants

Country Status (8)

Country Link
US (3) US20140065113A1 (fr)
EP (1) EP2707021B1 (fr)
JP (5) JP2014517690A (fr)
CN (2) CN112028985A (fr)
AU (1) AU2012253652B2 (fr)
CA (1) CA2835453A1 (fr)
IL (1) IL229316B (fr)
WO (1) WO2012154759A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL307628A (en) * 2013-02-20 2023-12-01 Minerva Biotechnologies Corp NME inhibitors and methods of using NME inhibitors
WO2016061396A1 (fr) * 2014-10-16 2016-04-21 Counsyl, Inc. Programme d'appel de variants
CN117736272B (zh) * 2024-02-19 2024-04-30 四川省医学科学院·四川省人民医院 一种具有促成骨功能的生物活性多肽

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0495910T3 (da) * 1989-10-18 2002-01-14 Us Health Fremstilling og anvendelse af humant nm23-H2-protein og derimod rettede antistoffer
US5958671A (en) * 1996-04-23 1999-09-28 Presidents And Fellows Of Harvard College Methods and compositions for regulating T cell subsets by modulating transcription factor activity
US20050112607A1 (en) * 1999-01-23 2005-05-26 Bamdad Cynthia C. Rapid and sensitive detection of protein aggregation
US7550143B2 (en) * 2005-04-06 2009-06-23 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
AU782496B2 (en) * 1999-07-13 2005-08-04 Bolder Biotechnology, Inc. Immunoglobulin fusion proteins
US6617135B1 (en) * 1999-08-09 2003-09-09 Emd Lexigen Research Center Corp. Multiple cytokine protein complexes
US20020169290A1 (en) * 2000-11-02 2002-11-14 Claus Bornaes New multimeric interferon beta polypeptides
WO2002036626A1 (fr) * 2000-11-02 2002-05-10 Maxygen Aps Polypeptides multimeres comportant une seule chaine
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030008820A1 (en) * 2001-03-27 2003-01-09 Massachusetts Institute Of Technology Methods and products related to FGF dimerization
EP1353182A3 (fr) * 2002-04-12 2004-02-04 Smithkline Beecham Corporation Procédé de prédiction des résultats des essais à base de cellules utilisant des profils de liaison
EP1553963A4 (fr) * 2002-09-24 2006-05-03 Burnham Inst Nouveaux agents modulant l'activite du recepteur eph
JP5068072B2 (ja) * 2003-06-27 2012-11-07 バイオジェン・アイデック・エムエイ・インコーポレイテッド 連結ペプチドを含む改変された結合分子
US20050054752A1 (en) * 2003-09-08 2005-03-10 O'brien John P. Peptide-based diblock and triblock dispersants and diblock polymers
BRPI0507174A (pt) * 2004-01-28 2008-04-01 Syntonix Pharmaceuticals Inc proteìnas de fusão hormÈnio-fc (fsh-fc) heterodiméricas estimuladoras de folìculo para o tratamento da infertilidade
KR101571027B1 (ko) * 2006-06-12 2015-11-23 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 효과기 기능을 갖는 단일쇄 다가 결합 단백질
WO2008070171A2 (fr) * 2006-12-06 2008-06-12 Minerva Biotechnologies Corp. Procédé d'identification et de manipulation de cellules
EP2310508A1 (fr) * 2008-07-02 2011-04-20 Emergent Product Development Seattle, LLC Protéines de liaison multi-cibles antagonistes du tgf-b
JP2012505636A (ja) * 2008-10-09 2012-03-08 ミネルバ バイオテクノロジーズ コーポレーション 細胞において多能性を誘導する方法
MX2011013385A (es) * 2009-06-11 2012-05-29 Minerva Biotechnologies Corp Metodos para cultivar celulas madre y celulas progenitoras.
WO2011103049A2 (fr) * 2010-02-16 2011-08-25 Immune Disease Institute, Inc. Procédé de criblage à la recherche d'interactions récepteurs/ligands
EP2686418A4 (fr) * 2011-03-17 2015-04-22 Minerva Biotechnologies Corp Procédé d'obtention de cellules souches pluripotentes

Also Published As

Publication number Publication date
US20240294590A1 (en) 2024-09-05
CN103930439A (zh) 2014-07-16
EP2707021A2 (fr) 2014-03-19
CA2835453A1 (fr) 2012-11-15
AU2012253652B2 (en) 2017-07-06
US20200062812A1 (en) 2020-02-27
US20140065113A1 (en) 2014-03-06
JP2022031824A (ja) 2022-02-22
JP2017061471A (ja) 2017-03-30
AU2012253652A1 (en) 2013-11-28
IL229316A0 (en) 2014-01-30
EP2707021C0 (fr) 2024-02-21
WO2012154759A2 (fr) 2012-11-15
EP2707021A4 (fr) 2015-08-05
JP2020039359A (ja) 2020-03-19
JP2024056702A (ja) 2024-04-23
JP6717725B2 (ja) 2020-07-01
CN112028985A (zh) 2020-12-04
JP2014517690A (ja) 2014-07-24
WO2012154759A3 (fr) 2014-05-01
EP2707021B1 (fr) 2024-02-21

Similar Documents

Publication Publication Date Title
HK1202045A1 (en) Lattice
AU334463S (en) Pot
EP2673635A4 (fr) Immunothérapie par l'intermédiaire d'apoe
EP2758925A4 (fr) Placement d'annonces
HK1210004A1 (en) Implant part
ZA201308104B (en) Overshot
ZA201306280B (en) Overshot
IL229316A0 (en) Genetically engineered growth factor variants
GB201209010D0 (en) No title
PL2484195T3 (pl) Pojazd do zbierania owoców
AU340010S (en) Armchairs
PL2529616T3 (pl) Zespół doniczki dla rośliny
PL119929U1 (pl) Konewka
GB201118937D0 (en) Prothesis
IL212930A (en) A plant pot
AU336892S (en) Growth punnet
AU339832S (en) Dish
GB201111783D0 (en) Implant
GB201105496D0 (en) Implant
GB201102581D0 (en) Implant
GB201117114D0 (en) Easy peasy beanie trellis
TWM433372U (en) Packaging-type straw structure
PL2478759T3 (pl) Doniczka na rośliny
GB201307357D0 (en) No title
GB201113486D0 (en) Project grow

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed